Globe Newswire (Wed, 24-Dec 11:23 AM ET)
PRNewswire (Tue, 23-Dec 10:18 AM ET)
Globe Newswire (Sat, 20-Dec 8:01 AM ET)
PRNewswire (Thu, 4-Dec 10:28 AM ET)
Globe Newswire (Sat, 29-Nov 8:51 AM ET)
Tvardi Therapeutics Reports No Efficacy Benefit in Phase 2 IPF Trial—What Does the Data Reveal?
Market Chameleon (Mon, 13-Oct 4:43 AM ET)
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Tvardi Therapeutics trades on the NASDAQ stock market under the symbol TVRD.
As of December 31, 2025, TVRD stock price climbed to $4.30 with 217,347 million shares trading.
TVRD has a beta of -1.08, meaning it tends to be less sensitive to market movements. TVRD has a correlation of 0.00 to the broad based SPY ETF.
TVRD has a market cap of $40.32 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that TVRD belongs to (by Net Assets): VTI, IWM, DWAS, VXF, IWN.
TVRD support price is $4.04 and resistance is $4.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TVRD shares will trade within this expected range on the day.
